Chon­dr­i­al bags a $22M A round for mi­to­chon­dr­i­al R&D; Ari­ad filed mar­ket­ing app for briga­tinib

• Deer­field has tak­en the lead on a $22.6 mil­lion Se­ries A for Chon­dr­i­al Ther­a­peu­tics, a Bala Cyn­wyd, PA-based biotech with a fo­cus on rare mi­to­chon­dr­i­al dis­eases. The biotech in-li­censed CTI-1601 for the treat­ment of Friedre­ich’s Atax­ia from In­di­ana Uni­ver­si­ty Re­search and Tech­nol­o­gy Corp. and Wake For­est Uni­ver­si­ty Health Sci­ences. Ca­r­ole Ben-Mai­mon was named CEO.

• Ari­ad says that it has sub­mit­ted a mar­ket­ing ap­pli­ca­tion for briga­tinib with the EMA. The can­cer drug, which fig­ured promi­nent­ly in Take­da’s $5.2 bil­lion buy­out deal, is al­ready un­der re­view at the FDA, where it faces an April 29 PDU­FA date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER